Benzinga | Dec 10, 2020 08:04AM EST

Biocept Reports Its Target Selector Liquid Biopsy Showed 'High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center'

Biocept, Inc. (NASDAQ:BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces results from a prospective study showing Target Selector(tm) was highly accurate in monitoring HER2 alterations in patients with metastatic breast cancer. The results were featured yesterday in a poster presentation by Vered Stearns, M.D., professor of oncology, breast cancer research chair in oncology, and director of the Women's Malignancies Disease Group at Johns Hopkins University School of Medicine/Johns Hopkins Sidney Kimmel Cancer Center, at the virtual 2020 San Antonio Breast Cancer Symposium(r) (SABC(r)). The poster can be found under the "breast cancer" tab here.



"Approximately 20% of newly diagnosed breast cancer is HER2 positive, but during treatment and as the disease progresses, HER2 receptor conversion may occur," said Dr. Stearns. "Once breast cancer metastasizes, it may be difficult to access multiple sites or perform serial tissue biopsies to monitor for conversion. In this study, liquid biopsy testing proved to be a highly sensitive and specific mechanism for monitoring HER2 receptor changes over time."

"Target Selector(tm) has been shown to be a highly sensitive blood-based testing method for identifying changes in HER2 status, and is less invasive, more time efficient and more cost effective compared to tissue biopsy," said Michael Nall, President and CEO. "Target Selector(tm) provides critical information to identify patients who may benefit from the addition of anti-HER2 therapy and those on anti-HER2 therapy for whom additional therapeutic options may warrant consideration."